残余胆固醇与心血管疾病相关的研究进展
Research Progress on the Relationship between Remnant Cholesteroland Cardiovascular Diseases
DOI: 10.12677/ACM.2024.142621, PDF,   
作者: 曹紫晨, 付真彦*：新疆医科大学第一附属医院心脏中心，新疆 乌鲁木齐
关键词: 残余胆固醇；心血管疾病；治疗；血脂代谢；Remnant Cholesterol； Cardiovascular Disease； Treatment； Serum Lipid Metabolism
摘要: 血脂异常被认为是心血管疾病发生和发展的罪魁祸首，近几十年来，以低密度脂蛋白胆固醇为靶点的降脂疗法的益处已研究明确，然而，即使降脂药物将低密度脂蛋白降至推荐浓度，以及高血压等其他风险因素得到很好控制后，发生ASCVD的风险仍然存在，近些年越来越多的研究发现，残余胆固醇在动脉粥样硬化性心血管疾病发病的残余风险中扮演着越来越重要的预测作用。现将关于残余胆固醇的最新研究做如下综述。
Abstract: Dyslipidemia is the main pathogenic factor in the occurrence and development of ASCVD. In recent decades, the benefits of lipid-lowering therapy targeting low-density lipoprotein cholesterol have been clearly studied. However, even after statins or new lipid-lowering drugs reduce low-density lipoprotein to the recommended concentration, and other risk factors such as hypertension are well controlled, the risk of ASCVD still exists. In recent years, more and more studies have found that Remnant cholesterol plays an increasingly important role in predicting the residual risk of athero-sclerotic cardiovascular disease. The latest research on Remnant cholesterol is reviewed as follows.
文章引用：曹紫晨, 付真彦. 残余胆固醇与心血管疾病相关的研究进展[J]. 临床医学进展, 2024, 14(2): 4474-4478. https://doi.org/10.12677/ACM.2024.142621

参考文献

[1] Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021. [Google Scholar] [CrossRef] [PubMed]
[2] Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188. [Google Scholar] [CrossRef] [PubMed]
[3] Esan, O. and Wierzbicki, A.S. (2021) Triglycerides and Cardiovascu-lar Disease. Current Opinion in Cardiology, 36, 469-477. [Google Scholar] [CrossRef] 
[4] Nordestgaard, B.G., Benn, M., Schnohr, P. and Tybja-erg-Hansen, A. (2007) Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA, 298, 299-308. [Google Scholar] [CrossRef] [PubMed]
[5] Duran, E.K. and Pradhan, A.D. (2021) Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease. Clinical Chemistry, 67, 183-196. [Google Scholar] [CrossRef] [PubMed]
[6] Jepsen, A.M.K., Langsted, A., Varbo, A., Bang, L.E., Kamstrup, P.R. and Nordestgaard, B.G. (2016) Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortal-ity in 5414 Patients with Ischemic Heart Disease. Clinical Chemistry, 62, 593-604. [Google Scholar] [CrossRef] [PubMed]
[7] Cao, Y.X., Zhang, H.W., Jin, J.L., et al. (2020) The Longitu-dinal Association of Remnant Cholesterol with Cardiovascular Outcomes in Patients with Diabetes and Pre-Diabetes. Cardiovascular Diabetology, 19, Article No. 104. [Google Scholar] [CrossRef] [PubMed]
[8] Ginsberg, H.N., Packard, C.J., Chapman, M.J., et al. (2021) Tri-glyceride-Rich Lipoproteins and Their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therapeutic Strategies—A Consensus Statement from the European Atherosclerosis Society. European Heart Journal, 42, 4791-4806. [Google Scholar] [CrossRef] [PubMed]
[9] Castañer, O., Pintó, X., Subirana, I., et al. (2020) Remnant Choles-terol, Not LDL Cholesterol, Is Associated with Incident Cardiovascular Disease. Journal of the American College of Cardiology, 76, 2712-2724. [Google Scholar] [CrossRef] [PubMed]
[10] Wadström, B.N., Wulff, A.B., Pedersen, K.M., Jensen, G.B. and Nordestgaard, B.G. (2022) Elevated Remnant Cholesterol Increases the Risk of Peripheral Artery Disease, Myocardial Infarction, and Ischaemic Stroke: A Cohort-Based Study. European Heart Journal, 43, 3258-3269. [Google Scholar] [CrossRef] [PubMed]
[11] Xu, J., Qu, P., Du, X., et al. (2021) Change in Postprandial Level of Remnant Cholesterol after a Daily Breakfast in Chinese Patients with Hypertension. Frontiers in Cardiovascular Medi-cine, 8, Article 685385. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, M.M., Huang, X., Xu, C., et al. (2022) High Remnant Cho-lesterol Level Potentiates the Development of Hypertension. Frontiers in Endocrinology, 13, Article 830347. [Google Scholar] [CrossRef] [PubMed]
[13] Doi, T., Langsted, A. and Nordestgaard, B.G. (2022) Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction. Journal of the American College of Cardiology, 79, 2383-2397. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, J., Jin, R., Jin, X., et al. (2023) Separate and Joint Associa-tions of Remnant Cholesterol Accumulation and Variability with Carotid Atherosclerosis: A Prospective Cohort Study. Journal of the American Heart Association, 12, e029352. [Google Scholar] [CrossRef] 
[15] Navarese, E.P., Vine, D., Proctor, S., et al. (2023) Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 43, e373-e380. [Google Scholar] [CrossRef] 
[16] Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A.B., Frikke-Schmidt, R. and Nordestgaard, B.G. (2013) Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology, 61, 427-436. [Google Scholar] [CrossRef] [PubMed]
[17] Nordestgaard, B.G., Nicholls, S.J., Langsted, A., Ray, K.K. and Tybjærg-Hansen, A. (2018) Advances in Lipid-Lowering Therapy through Gene-Silencing Technologies. Nature Re-views Cardiology, 15, 261-272. [Google Scholar] [CrossRef] [PubMed]
[18] Kaltoft, M., Langsted, A. and Nordestgaard, B.G. (2020) Triglycerides and Remnant Cholesterol Associated with Risk of Aortic Valve Stenosis: Mendelian Randomization in the Copenhagen General Population Study. European Heart Journal, 41, 2288-2299. [Google Scholar] [CrossRef] [PubMed]
[19] Vallejo-Vaz, A.J., Fayyad, R., Boekholdt, S.M., et al. (2018) Tri-glyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 138, 770-781. [Google Scholar] [CrossRef] 
[20] Tsunoda, F., Asztalos, I.B., Horvath, K.V., Steiner, G., Schaefer, E.J. and Asztalos, B.F. (2016) Fenofibrate, HDL, and Cardiovascular Disease in Type-2 Diabetes: The DAIS Trial. Atherosclerosis, 247, 35-39. [Google Scholar] [CrossRef] [PubMed]
[21] Toth, P.P., Hamon, S.C., Jones, S.R., et al. (2016) Effect of Alirocumab on Specific Lipoprotein Non-High-Density Lipoprotein Cholesterol and Subfractions as Measured by the Vertical Auto Profile Method: Analysis of 3 Randomized Trials versus Placebo. Lipids in Health and Disease, 15, Arti-cle No. 28. [Google Scholar] [CrossRef] [PubMed]

为你推荐